GI Innovation, Inc.
KKRX:3585707,820.00
KRW
-240.00
(-2.98%)
ISIN
KR7358570000
Return %
Stock
S&P 500
1Y
-47.90
14.20
3Y
-3.79
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 82
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Room 1116 of A-dong, Songpa-daero 167 Seoul SL South Korea 5855
- IPO Date
- Mar 30, 2023
- Website
- gi-innovation.com
- Similar Companies
- Business
- GI Innovation, Inc. (KOSDAQ: 358570) operates as a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of next-generation fusion protein therapeutics targeting immuno-oncology, allergic diseases, metabolic disorders, and fibrosis; the firm leverages its proprietary GI-SMART™ high-throughput screening platform and GI-SMARTab™ bispecific antibody program to discover and optimize multi-targeting biologics for oncology and immunology indications. Core pipeline assets include GI-101 and its subcutaneous formulation GI-102, IL-7/IL-2 fusion proteins in Phase II trials for solid tumors such as melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial cancer; GI-301, an IgE-Fcγ fusion protein in Phase I for IgE-mediated allergies; GI-108, a metabolic immuno-oncology candidate; GI-30N for allergic and fibrotic diseases; GI-20N for obesity and metabolic conditions; and earlier-stage programs like GI-305 and NASH therapies. Headquartered in Seoul, South Korea, where it was founded in 2017, the company conducts operations primarily in South Korea, the United States, and China, generating revenue through technology transfers, licensing deals, and funding for its preclinical and clinical-stage assets targeting global pharmaceutical partners and patients with unmet needs in cancer immunotherapy and chronic inflammatory conditions. Recent developments encompass a January 2025 memorandum of understanding with LaNova Medicines to advance GI-102 in combination with Claudin18.2-targeting ADC LM-302 for metastatic pancreatic cancer following promising preclinical data; advancement to semi-finalist status in May 2025 for the XPRIZE Healthspan competition with sister company GI Biome, showcasing low-dose GI-102 plus GIB-7 synbiotic as an anti-aging therapy and securing USD 250,000 in milestone funding; a 20 billion won (approximately USD 14.5 million) fundraising round in 2024 via convertible preference stock and bonds from investors including Brain Asset Management and new participants like Welcome Asset Management to support GI-305 allergy and GI-20N anti-obesity programs; receipt of U.S. FDA Fast Track Designation in September 2025 for GI-102 in refractory melanoma; and European patent registration for GI-101A subcutaneous formulation in September 2025, bolstering its intellectual property for Phase II expansion.